SHR-1316

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

Reverse Triple Negative Immune Resistant Breast Cancer

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors